# US 11,299,549 B2 · Humanized BCMA antibody and BCMA-CAR-T cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,299,549 B2
- Document ID: US11299549B2
- Status: Granted
- Kind: B2
- Application number: 17/493,386
- Filed: 2021-10-04
- Published: 2022-01-20
- Granted: 2022-04-12
- Earliest claimed: 2019-01-16
- Assignees: Caribou Biosciences, Inc.
- Applicants: Caribou Biosciences, Inc.
- Inventors: Lijun Wu; Vita Golubovskaya
- Web page: https://patentgrep.com/patent/US11299549B2

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/46: characterised by the cancer treated
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.

## Claims

### Claim 1

A therapeutic agent for inhibiting growth of BCMA-positive tumors, the agent comprising immune cells expressing an anti-BCMA chimeric antigen receptor (CAR) having an anti-BCMA single-chain variable fragment (scFv) comprising:
a. a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region VL) comprising the amino acid sequence of SEQ ID NO: 5;
b. a transmembrane domain;
c. a co-stimulatory domain; and
d. an activating domain;
and further comprising an excipient.

### Claim 2 (depends on 1)

The therapeutic agent of claim 1, wherein the immune cells are selected from T cells, NK cells, macrophages, and hematopoietic cells.

### Claim 3 (depends on 1)

The therapeutic agent of claim 1, further comprising one or more of a checkpoint inhibitor, a targeted therapy, and a small molecule tumor inhibitor.

### Claim 4 (depends on 1)

The therapeutic agent of claim 1, further comprising a safety switch agent selected from t-EGFR, Rituximab-CD34-Rituximab (RQR), and inducible caspase-9.

### Claim 5 (depends on 1)

The therapeutic agent of claim 1, wherein the transmembrane domain of the CAR is selected from the group consisting of a T cell receptor α chain, a T cell receptor β chain, a CD3 zeta chain, a CD28, a CD3ε, a CD45, a CD4, a CD5, a CD8, a CD9, a CD16, a CD22, a CD33, a CD37, a CD64, a CD80, a CD86, a CD134, a CD137, an ICOS, a CD154, and a GITR.

### Claim 6 (depends on 1)

The therapeutic agent of claim 1, wherein the transmembrane domain of the CAR comprises a transmembrane domain of a CD8.

### Claim 7 (depends on 1)

The therapeutic agent of claim 1, wherein the co-stimulatory domain of the CAR is selected from the group consisting of a CD28, a 4-1BB, a GITR, an ICOS-1, a CD27, an OX-40, and a DAP10.

### Claim 8 (depends on 1)

The therapeutic composition of claim 1, wherein the co-stimulatory domain of the CAR comprises a 4-1BB co-stimulatory domain.

### Claim 9 (depends on 1)

The therapeutic agent of claim 1, wherein the activating domain of the CAR comprises a CD3 zeta activating domain.

### Claim 10 (depends on 1)

The therapeutic agent of claim 1, wherein the transmembrane domain of the CAR comprises a transmembrane domain of a CD8, the co-stimulatory domain comprises a 4-1BB co-stimulatory domain, and the activating domain comprises a CD3 zeta activating domain.

### Claim 11 (depends on 1)

The therapeutic agent of claim 1, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 17.

### Claim 12

A method of inhibiting growth of a BCMA-positive tumor, the method comprising administering to a patient having a tumor an effective number of immune cells expressing an anti-BCMA chimeric antigen receptor (CAR) having an anti-BCMA single-chain variable fragment (scFv) comprising: a. a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region VL) comprising the amino acid sequence of SEQ ID NO: 5;
b. a transmembrane domain;
c. a co-stimulatory domain; and
d. an activating domain;
and further comprising an excipient.

### Claim 13 (depends on 12)

The method of claim 12, wherein the immune cells are selected from T cells, NK cells, macrophages, and hematopoietic cells.

### Claim 14 (depends on 12)

The method of claim 12, further comprising administering to the patient one or more of a checkpoint inhibitor, a targeted therapy or a small molecule tumor inhibitor.

### Claim 15 (depends on 12)

The method of claim 12, wherein the immune cells comprise a safety switch agent selected from t-EGFR, Rituximab-CD34-Rituximab (RQR), and inducible caspase-9.

### Claim 16 (depends on 12)

The method of claim 12, wherein the transmembrane domain of the CAR is selected from the group consisting of a T cell receptor α chain, a T cell receptor β chain, a CD3 zeta chain, a CD28, a CD3ε, a CD45, a CD4, a CD5, a CD8, a CD9, a CD16, a CD22, a CD33, a CD37, a CD64, a CD80, a CD86, a CD134, a CD137, an ICOS, a CD154, and a GITR.

### Claim 17 (depends on 12)

The method of claim 12, wherein the transmembrane domain of the CAR comprises a transmembrane domain of a CD8.

### Claim 18 (depends on 12)

The method of claim 12, wherein the co-stimulatory domain of the CAR is selected from the group consisting of a CD28, a 4-1BB, a GITR, an ICOS-1, a CD27, an OX-40, and a DAP10.

### Claim 19 (depends on 12)

The method of claim 12, wherein the co-stimulatory domain of the CAR comprises a 4-1BB co-stimulatory domain.

### Claim 20 (depends on 12)

The method of claim 12, wherein the activating domain of the CAR comprises a CD3 zeta activating domain.

### Claim 21 (depends on 12)

The method of claim 12, wherein the transmembrane domain of the CAR comprises a transmembrane domain of a CD8, the co-stimulatory domain comprises a 4-1BB co-stimulatory domain, and the activating domain comprises a CD3 zeta activating domain.

### Claim 22 (depends on 12)

The method of claim 12, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 17.